與「Leonardo De Luca」相符的使用者個人學術檔案

Leonardo De Luca

Direttore SC Cardiologia, Fondazione IRCCS Policlinico San Matteo, Pavia
在 smatteo.pv.it 的電子郵件地址已通過驗證
被引用 10122 次

Congestion in acute heart failure syndromes: an essential target of evaluation and treatment

M Gheorghiade, G Filippatos, L De Luca… - The American journal of …, 2006 - Elsevier
Patients with acute heart failure syndromes (AHFS) typically present with signs and symptoms
of systemic and pulmonary congestion at admission. However, elevated left ventricular (LV…

Pathophysiologic targets in the early phase of acute heart failure syndromes

M Gheorghiade, L De Luca, GC Fonarow… - The American journal of …, 2005 - Elsevier
An episode of acute heart failure syndromes (AHFS) can be defined as a rapid or gradual
onset of signs and symptoms of heart failure (HF) that result in hospital admission and can …

Evidence-based use of levosimendan in different clinical settings

L De Luca, WS Colucci, MS Nieminen… - European heart …, 2006 - academic.oup.com
Levosimendan is a new calcium sensitizer and K-ATP channel opener. Compared with other
inodilators, it improves myocardial contractility without increasing oxygen requirements and …

Reperfusion therapy for ST elevation acute myocardial infarction 2010/2011: current status in 37 ESC countries

…, K Twomey, K Daly, S Matetzky, L De Luca… - European heart …, 2014 - academic.oup.com
Aims Primary percutaneous coronary intervention (PPCI) is the preferred reperfusion therapy
in ST-elevation myocardial infarction (STEMI). We conducted this study to evaluate the …

Impact of intracoronary aspiration thrombectomy during primary angioplasty on left ventricular remodelling in patients with anterior ST elevation myocardial infarction

L De Luca, G Sardella, CJ Davidson, G De Persio… - Heart, 2006 - heart.bmj.com
Objective: To evaluate prospectively the impact on left ventricular (LV) remodelling of an
intracoronary aspiration thrombectomy device as adjunctive therapy in primary percutaneous …

Navigating the crossroads of coronary artery disease and heart failure

M Gheorghiade, G Sopko, L De Luca, EJ Velazquez… - Circulation, 2006 - Am Heart Assoc
Among patients with HF or evidence of LV dysfunction after acute MI enrolled in the Optimal
Trial in Myocardial Infarction With the Angiotensin II Antagonist Losartan (OPTIMAAL), …

Effects of levosimendan on systemic and regional hemodynamics in septic myocardial depression

…, M Singer, M Rocco, G Conti, L De Luca… - Intensive care …, 2005 - Springer
Objective Calcium desensitization plays an important part in the pathophysiology of septic
myocardial depression. We postulated that levosimendan, a new calcium sensitizer, would be …

International Expert Consensus on Switching Platelet P2Y12 Receptor–Inhibiting Therapies

…, D Alexopoulos, PA Gurbel, W Hochholzer, L De Luca… - Circulation, 2017 - Am Heart Assoc
Dual antiplatelet therapy with aspirin and a P2Y 12 inhibitor is the treatment of choice for the
prevention of atherothrombotic events in patients with acute coronary syndromes and for …

Clinical impact of thrombectomy in acute ST-elevation myocardial infarction: an individual patient-data pooled analysis of 11 trials

…, PS Orrego, D Antoniucci, L De Luca… - European heart …, 2009 - academic.oup.com
Aims Thrombectomy in patients with ST-elevation myocardial infarction (STEMI) undergoing
percutaneous coronary intervention (PCI) is associated to better myocardial reperfusion. …

Reassessment of dobutamine, dopamine, and milrinone in the management of acute heart failure syndromes

M Bayram, L De Luca, MB Massie… - The American journal of …, 2005 - Elsevier
The appropriate role of intravenous inodilator therapy (inotropic agents with vasodilator
properties) in the management of acute heart failure syndromes (AHFS) has long been a subject …